JOP20200192A1 - Anti-tigit antibodies - Google Patents
Anti-tigit antibodiesInfo
- Publication number
- JOP20200192A1 JOP20200192A1 JOP/2020/0192A JOP20200192A JOP20200192A1 JO P20200192 A1 JOP20200192 A1 JO P20200192A1 JO P20200192 A JOP20200192 A JO P20200192A JO P20200192 A1 JOP20200192 A1 JO P20200192A1
- Authority
- JO
- Jordan
- Prior art keywords
- tigit antibodies
- antibodies
- tigit
- cancer
- diseases
- Prior art date
Links
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462038912P | 2014-08-19 | 2014-08-19 | |
US201562126733P | 2015-03-02 | 2015-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200192A1 true JOP20200192A1 (en) | 2022-10-30 |
Family
ID=53938463
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2015/0195A JO3664B1 (en) | 2014-08-19 | 2015-08-17 | Anti-tigit antibodies |
JOP/2020/0192A JOP20200192A1 (en) | 2014-08-19 | 2020-08-05 | Anti-tigit antibodies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2015/0195A JO3664B1 (en) | 2014-08-19 | 2015-08-17 | Anti-tigit antibodies |
Country Status (31)
Country | Link |
---|---|
US (4) | US20160355589A1 (en) |
EP (1) | EP3183267A1 (en) |
JP (3) | JP6920194B2 (en) |
KR (2) | KR102321168B1 (en) |
CN (2) | CN113583131A (en) |
AP (1) | AP2017009765A0 (en) |
AU (3) | AU2015305754B2 (en) |
BR (1) | BR112017003108A8 (en) |
CA (1) | CA2957722C (en) |
CL (2) | CL2017000310A1 (en) |
CO (1) | CO2017001561A2 (en) |
CR (1) | CR20170060A (en) |
DO (1) | DOP2017000046A (en) |
EA (1) | EA036311B1 (en) |
GE (1) | GEP20217331B (en) |
GT (1) | GT201700033A (en) |
IL (1) | IL250583B (en) |
JO (2) | JO3664B1 (en) |
MA (1) | MA40475A (en) |
MD (1) | MD4733C1 (en) |
MX (2) | MX2017002229A (en) |
MY (2) | MY184288A (en) |
NI (1) | NI201700019A (en) |
PE (1) | PE20170289A1 (en) |
PH (1) | PH12017500296A1 (en) |
SG (1) | SG11201701161QA (en) |
TN (1) | TN2017000024A1 (en) |
TW (2) | TWI790593B (en) |
UA (1) | UA122395C2 (en) |
WO (1) | WO2016028656A1 (en) |
ZA (1) | ZA201700955B (en) |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008266951B2 (en) | 2007-06-18 | 2013-12-12 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor PD-1 |
EP2279412B1 (en) | 2008-04-09 | 2017-07-26 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
ES2707580T3 (en) | 2011-09-23 | 2019-04-04 | Oncomed Pharm Inc | VEGF / DLL4 binding agents and uses thereof |
PL3081576T3 (en) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
KR102433464B1 (en) | 2014-05-28 | 2022-08-17 | 아게누스 인코포레이티드 | Anti-gitr antibodies and methods of use thereof |
UA122395C2 (en) * | 2014-08-19 | 2020-11-10 | Мерк Шарп Енд Доум Корп. | ANTIBODY AGAINST TIGIT |
SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
PT3653221T (en) | 2015-02-19 | 2022-11-08 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
EP3978929A1 (en) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
MA42043A (en) | 2015-05-07 | 2018-03-14 | Agenus Inc | ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF |
TWI715587B (en) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit-binding agents and uses thereof |
JP6976241B2 (en) | 2015-08-14 | 2021-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Anti-TIGIT antibody |
US10323091B2 (en) | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
EP3344658B1 (en) | 2015-09-02 | 2022-05-11 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) |
EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
RU2729379C1 (en) | 2015-10-01 | 2020-08-06 | Потенза Терапевтикс, Инк. | Anti-tigit antigen-binding proteins and methods for use thereof |
MY189018A (en) | 2015-11-18 | 2022-01-19 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
CN116063542A (en) | 2015-12-02 | 2023-05-05 | 阿吉纳斯公司 | Antibodies and methods of use thereof |
UA125898C2 (en) * | 2016-03-04 | 2022-07-06 | Джн Байосайєнсіз, Ллк | Antibodies to tigit |
US10894823B2 (en) | 2016-03-24 | 2021-01-19 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
SG10201912563XA (en) | 2016-05-27 | 2020-02-27 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
EP3471754A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 antibodies |
RU2764548C2 (en) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Anti-icos antibodies |
PT3347379T (en) * | 2016-08-17 | 2020-02-18 | Compugen Ltd | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof |
CN107815467B (en) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | Preparation method and application of humanized gene modified animal model |
WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
KR20230133934A (en) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | Anti-lag-3 antibodies and methods of use thereof |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
AU2017355512A1 (en) | 2016-11-04 | 2019-05-23 | Aximmune, Inc. | Beta-alethine, immune modulators, and uses thereof |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
CN110662552A (en) * | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | Methods of cancer treatment comprising TIGIT binding agents |
WO2018102746A1 (en) * | 2016-12-02 | 2018-06-07 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to tigit |
AU2017373945A1 (en) | 2016-12-07 | 2019-06-20 | Agenus Inc. | Antibodies and methods of use thereof |
US10232053B2 (en) | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
US10537637B2 (en) | 2017-01-05 | 2020-01-21 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
AU2018226646A1 (en) * | 2017-03-03 | 2019-09-19 | Rinat Neuroscience Corp. | Anti-GITR antibodies and methods of use thereof |
JOP20190203A1 (en) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | Anti-tigit antigen-binding proteins and methods of use thereof |
US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
KR20190137911A (en) | 2017-04-21 | 2019-12-11 | 신라젠(주) | Anticancer Vaccinia Virus and Gateway Inhibitor Combination Therapy |
KR20190141223A (en) | 2017-04-26 | 2019-12-23 | 브리스톨-마이어스 스큅 컴퍼니 | Antibody Production Methods to Minimize Disulfide Bond Reduction |
MA50957A (en) | 2017-05-01 | 2020-10-14 | Agenus Inc | ANTI-TIGIT ANTIBODIES AND THEIR METHODS OF USE |
JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
EP3618855A4 (en) * | 2017-05-02 | 2021-02-17 | Merck Sharp & Dohme Corp. | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
JP7348072B2 (en) | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | Triple combination antibody therapy |
WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
SG11202000660QA (en) * | 2017-07-27 | 2020-02-27 | Iteos Therapeutics Sa | Anti-tigit antibodies |
BE1025333B1 (en) * | 2017-07-27 | 2019-01-23 | Iteos Therapeutics S.A. | ANTI-TIGIT ANTIBODIES |
WO2019023504A1 (en) | 2017-07-27 | 2019-01-31 | Iteos Therapeutics Sa | Anti-tigit antibodies |
EP3689909A4 (en) * | 2017-09-29 | 2021-12-29 | Jiangsu Hengrui Medicine Co., Ltd. | Tigit antibody, antigen-binding fragment thereof, and medical use thereof |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
CA3082280A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
TWI816729B (en) * | 2017-12-30 | 2023-10-01 | 英屬開曼群島商百濟神州有限公司 | Anti-tigit antibodies and their use as therapeutics and diagnostics |
EP3740508A4 (en) * | 2018-01-15 | 2022-03-23 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against tigit |
WO2019152574A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
JP7156607B2 (en) * | 2018-02-06 | 2022-10-19 | アイ-エムエービー バイオファーマ (ハンジョウ) カンパニー リミテッド | Antibodies against T-cell immunoreceptor (TIGIT) with IG and ITIM domains and uses thereof |
MX2020008795A (en) | 2018-02-28 | 2020-10-08 | Yuhan Corp | Anti-tigit antibodies and uses thereof. |
CN111918873A (en) | 2018-03-27 | 2020-11-10 | 百时美施贵宝公司 | Real-time monitoring of titre using UV signals |
US20190300610A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
AR114789A1 (en) * | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM |
JP2021522801A (en) | 2018-05-09 | 2021-09-02 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | Antibodies specific for humannectin 4 |
SG11202011461TA (en) | 2018-06-01 | 2020-12-30 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
EP3813880A4 (en) | 2018-06-29 | 2022-07-13 | Gensun Biopharma Inc. | Antitumor immune checkpoint regulator antagonists |
SG11202100746WA (en) * | 2018-07-25 | 2021-03-30 | Innovent Biologics Suzhou Co Ltd | Anti-tigit antibody and use thereof |
AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
CN112996805A (en) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | Multi-chain chimeric polypeptides and uses thereof |
AU2019328313A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
CN110511912B (en) * | 2018-08-30 | 2024-03-22 | 浙江煦顼技术有限公司 | Functional modulation of immune cells |
WO2020047473A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
EP3877418A4 (en) * | 2018-11-05 | 2022-08-17 | Merck Sharp & Dohme Corp. | Dosing regimen of anti-tigit antibody for treatment of cancer |
JP2022514702A (en) | 2018-12-21 | 2022-02-14 | オーエスイー・イミュノセラピューティクス | Bifunctional anti-PD-1 / IL-7 molecule |
KR20210113282A (en) | 2019-01-07 | 2021-09-15 | 아이테오스 벨지움 에스에이 | anti-TIGIT antibody |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
EP3938396A1 (en) | 2019-03-11 | 2022-01-19 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
CN111744013B (en) * | 2019-03-29 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | Methods and pharmaceutical combinations for treating diseases using anti-TIGIT antibodies in combination with PD-1 inhibitors |
CN111744007B (en) * | 2019-03-29 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | anti-TIGIT antibody pharmaceutical composition and application thereof |
WO2020237221A1 (en) | 2019-05-23 | 2020-11-26 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
TWI760751B (en) * | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit and pd-1/tigit-binding molecules |
JP7297095B2 (en) * | 2019-06-13 | 2023-06-23 | グリーン クロス コーポレーション | ANTIBODY AGAINST TIGIT AND USES THEREOF |
US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
US10851157B2 (en) | 2019-07-01 | 2020-12-01 | Gensun Biopharma, Inc. | Antagonists targeting the TGF-β pathway |
AU2020314129A1 (en) * | 2019-07-15 | 2022-02-24 | Shanghai Junshi Biosciences Co., Ltd. | Anti-tigit antibodies and application thereof |
US20220251194A1 (en) * | 2019-07-30 | 2022-08-11 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bicpecific antibodies |
US11667709B2 (en) | 2019-09-24 | 2023-06-06 | Industrial Technology Research Institute | Anti-TIGIT antibodies and methods of use |
CA3155173A1 (en) * | 2019-09-27 | 2021-04-01 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
US20220340660A1 (en) * | 2019-10-01 | 2022-10-27 | Merck Sharp & Dohme Corp. | Biomarkers for anti-tigit antibody treatment |
IL292757A (en) | 2019-11-05 | 2022-07-01 | Merck Patent Gmbh | Anti-tigit antibodies and uses thereof |
WO2021091960A1 (en) | 2019-11-05 | 2021-05-14 | Jounce Therapeutics, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
TW202124452A (en) * | 2019-11-14 | 2021-07-01 | 中國大陸商上海藥明生物技術有限公司 | A novel antibody against tigit |
US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
TW202136287A (en) | 2019-12-17 | 2021-10-01 | 法商Ose免疫治療公司 | Bifunctional molecules comprising an il-7 variant |
MX2022008412A (en) | 2020-01-07 | 2022-08-08 | Univ Texas | Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy. |
JP2023519106A (en) | 2020-02-11 | 2023-05-10 | エイチシーダブリュー バイオロジックス インコーポレイテッド | CHROMATOGRAPHIC RESIN AND USES THEREOF |
EP4103601A2 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
CA3170025A1 (en) | 2020-03-13 | 2021-09-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pvrig binding protein and its medical uses |
WO2021216468A1 (en) * | 2020-04-19 | 2021-10-28 | Askgene Pharma Inc. | Human tigit specific single domain antibodies and methods of use |
CN115836087A (en) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | anti-CD 26 protein and application thereof |
CN113563470B (en) | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | Antibody combined with TIGIT antigen and preparation method and application thereof |
WO2021224438A1 (en) | 2020-05-07 | 2021-11-11 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
CN114507284B (en) * | 2020-05-09 | 2023-05-26 | 华博生物医药技术(上海)有限公司 | Antibodies against TIGIT, methods of preparation and uses thereof |
IL298608A (en) | 2020-06-01 | 2023-01-01 | Hcw Biologics Inc | Methods of treating aging-related disorders |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
JP2023528036A (en) | 2020-06-02 | 2023-07-03 | アーカス バイオサイエンシズ インコーポレイティド | Antibody to TIGIT |
BR112022025801A2 (en) | 2020-06-18 | 2023-10-03 | Hoffmann La Roche | METHODS FOR TREATING A PATIENT AND FOR TREATING A PATIENT WITH ADVANCED ESCC, KIT, ANTIBODY, USE OF AN ANTIBODY, AND USE OF A BINDING ANTAGONIST |
WO2021258337A1 (en) * | 2020-06-24 | 2021-12-30 | Huahui Health Ltd. | Human monoclonal antibodies against tigit for immune related diseases |
CN111718415B (en) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | anti-TIGIT nano antibody and application thereof |
TW202216778A (en) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit and cd112r blockade |
WO2022044010A1 (en) | 2020-08-26 | 2022-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections |
JP2023544410A (en) | 2020-10-05 | 2023-10-23 | ブリストル-マイヤーズ スクイブ カンパニー | Methods for concentrating proteins |
JP2023548538A (en) | 2020-11-08 | 2023-11-17 | シージェン インコーポレイテッド | combination therapy |
US11028172B1 (en) * | 2020-11-10 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Anti-TIGIT antibodies and uses thereof |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
TW202222345A (en) * | 2020-11-26 | 2022-06-16 | 大陸商信達生物製藥(蘇州)有限公司 | Formulations containing anti-tigit/pd-1 bispecific antibody as well as preparation method and use thereof |
US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2022124864A1 (en) * | 2020-12-10 | 2022-06-16 | 주식회사 유틸렉스 | Anti-tigit antibody and use thereof |
TW202241935A (en) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | Chimeric antigen receptor system with adaptable receptor specificity |
US20240050646A1 (en) * | 2020-12-22 | 2024-02-15 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
JP2024500190A (en) * | 2020-12-22 | 2024-01-04 | レジーナ イー. ヘルツリンガー, | Methods, systems, and devices for administering monoclonal and/or polyclonal antibody treatments by bolus injection |
US11806507B2 (en) * | 2020-12-22 | 2023-11-07 | Regina E. HERZLINGER | Methods, systems, and apparatus for administering an antibody treatment via infusion |
WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
WO2022152245A1 (en) | 2021-01-14 | 2022-07-21 | 上海君实生物医药科技股份有限公司 | Anti-tigit antibody pharmaceutical composition and application thereof |
CN114984227A (en) * | 2021-03-02 | 2022-09-02 | 百奥泰生物制药股份有限公司 | Application of anti-TIGIT antibody in drug combination |
WO2022184068A1 (en) * | 2021-03-02 | 2022-09-09 | 百奥泰生物制药股份有限公司 | Application of anti-tigit antibody in treating tumors or cancers |
AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
BR112023020662A2 (en) | 2021-04-09 | 2024-02-06 | Seagen Inc | CANCER TREATMENT METHODS WITH ANTI-TIGIT ANTIBODIES |
US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
TW202304965A (en) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof |
CN117916263A (en) | 2021-05-10 | 2024-04-19 | 美帝马布生物公司 | Anti-TIGIT antibodies and uses thereof |
CN116940595A (en) * | 2021-05-18 | 2023-10-24 | 苏州鑫康合生物医药科技有限公司 | anti-TIGIT antibodies and uses thereof |
CN115466327A (en) * | 2021-06-10 | 2022-12-13 | 北京天广实生物技术股份有限公司 | Antibodies that bind to TIGIT and uses thereof |
TW202320848A (en) | 2021-07-28 | 2023-06-01 | 美商建南德克公司 | Methods and compositions for treating cancer |
WO2023036340A1 (en) * | 2021-09-13 | 2023-03-16 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Protein complexes targeting il21 pathway |
CA3231553A1 (en) | 2021-09-15 | 2023-03-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody |
TW202328195A (en) | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Proteins that specifically bind to pd-1 and the pharmaceutical use thereof |
CN115838424A (en) * | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | Monoclonal antibody targeting TIGIT |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
CN114181310B (en) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | anti-TIGIT antibody, and pharmaceutical composition and use thereof |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2023215719A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023239226A1 (en) * | 2022-06-10 | 2023-12-14 | 메디맵바이오 주식회사 | Fusion protein comprising antibody binding specifically to tigit and interleukin-15, and use thereof |
KR20230171885A (en) * | 2022-06-10 | 2023-12-21 | 메디맵바이오 주식회사 | Fusion protein comprising anti-TIGIT antibody, interleukin-15, and interleukin-15 receptor alpha sushi domain, and uses thereof |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
JP2532858B2 (en) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | Transformed myeloma cell line |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
DE3785186T2 (en) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
ATE135370T1 (en) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
DK1136556T3 (en) | 1991-11-25 | 2005-10-03 | Enzon Inc | Process for the preparation of multivalent antigen-binding proteins |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
DK0656946T4 (en) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobulins without light chains |
AU6796094A (en) | 1993-04-29 | 1994-11-21 | Raymond Hamers | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae) |
JPH08511420A (en) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | Body |
US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
ES2258817T3 (en) | 1997-05-21 | 2006-09-01 | Biovation Limited | METHOD FOR THE PRODUCTION OF NON-IMMUNOGEN PROTEINS. |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
US6329511B1 (en) | 1998-12-01 | 2001-12-11 | Protein Design Labs, Inc. | Humanized antibodies to γ-interferon |
KR100940380B1 (en) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | Polypeptide Variants with Altered Effector Function |
US7368527B2 (en) | 1999-03-12 | 2008-05-06 | Human Genome Sciences, Inc. | HADDE71 polypeptides |
EP1173462A1 (en) | 1999-03-26 | 2002-01-23 | Human Genome Sciences, Inc. | 50 human secreted proteins |
ES2571230T3 (en) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedure to control the activity of an immunofunctional molecule |
JP4668498B2 (en) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | Method for producing polypeptide |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
AU7684201A (en) | 2000-06-28 | 2002-01-08 | Glycofi Inc | Methods for producing modified glycoproteins |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6374470B1 (en) | 2000-10-06 | 2002-04-23 | Milliken & Company | Face plate for spun-like textured yarn |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
US20060182755A1 (en) | 2002-09-11 | 2006-08-17 | Genentech, Inc. | Novel composition and methods for the treatment of psoriasis |
ATE493433T1 (en) | 2002-09-11 | 2011-01-15 | Genentech Inc | NEW COMPOSITION AND METHOD FOR TREATING IMMUNE DISEASES |
WO2004035537A2 (en) | 2002-10-16 | 2004-04-29 | Euro-Celtique S.A. | Antibodies that bind cell-associated ca 125/o772p and methods of use thereof |
US20090047213A1 (en) * | 2003-04-14 | 2009-02-19 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
WO2005120571A2 (en) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
CA2573745A1 (en) | 2004-07-21 | 2007-01-12 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
CN101023102B (en) * | 2004-09-17 | 2013-05-29 | 霍夫曼-拉罗奇有限公司 | Anti-OX40L antibodies |
EP1891107B1 (en) | 2005-05-12 | 2011-07-06 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
KR101245462B1 (en) | 2005-07-08 | 2013-03-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Sp35 antibodies and uses thereof |
AU2007311946A1 (en) * | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient |
AU2007334264A1 (en) * | 2006-11-15 | 2008-06-26 | Medarex, Inc. | Human monoclonal antibodies to BTLA and methods of use |
EP2115002B1 (en) * | 2007-02-02 | 2014-08-20 | Baylor Research Institute | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
BRPI0807710B1 (en) * | 2007-02-23 | 2021-12-14 | Merck Sharp & Dohme Corp | ANTIBODIES THAT BIND HUMAN IL-23P19 AND IL-23, ANTIBODY, ISOLATED NUCLEIC ACID, EXPRESSION VECTOR, MICROBIAL HOST CELL, METHOD OF PRODUCTION OF A POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION |
BRPI0809594A2 (en) | 2007-04-03 | 2019-08-27 | Micromet Ag | polypeptide, nucleic acid sequence, vector, host, process for producing a polypeptide, pharmaceutical composition, use of a polypeptide, method for preventing, treating or ameliorating a disease in an individual in need thereof, kit, method for the identification of a polypeptide (s) |
AU2015202123B2 (en) | 2008-04-09 | 2017-06-15 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
EP2279412B1 (en) | 2008-04-09 | 2017-07-26 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
ES2624835T3 (en) | 2009-08-06 | 2017-07-17 | Immunas Pharma, Inc. | Antibodies that specifically bind to the A beta oligomers and use thereof |
CA2775573A1 (en) | 2009-10-09 | 2011-04-14 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her 3 antibodies |
CN102781958B (en) | 2009-12-05 | 2017-07-11 | 马尔瓦有限责任公司 | Based on the malaria vaccine for pushing up multiple worm Ferlin, Ferlin sample albumen and other albumen for containing C2 domains |
EA024701B1 (en) * | 2010-04-13 | 2016-10-31 | Селлдекс Терапьютикс Инк. | Antibodies that bind human cd27 and uses thereof |
BR112012031329A2 (en) | 2010-06-09 | 2016-10-11 | Zymogenetics Inc | vstm3 dimeric fusion proteins and related compositions and methods |
PT2609118T (en) | 2010-08-23 | 2017-03-22 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
UA112434C2 (en) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | ANTIGENCY BINDING SPECIFICALLY Binds to ALL |
US9205144B2 (en) | 2011-06-03 | 2015-12-08 | Dana-Farber Cancer Institute, Inc. | Identification of conserved peptide blocks in homologous polypeptides |
KR20130062168A (en) | 2011-12-02 | 2013-06-12 | 고려대학교 산학협력단 | Recombinant fluorescent nanoparticles |
US9732156B2 (en) | 2012-02-29 | 2017-08-15 | Gilead Biologics, Inc. | Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9 |
ES2875535T3 (en) | 2012-03-29 | 2021-11-10 | Biogen Ma Inc | Biomarkers for use in Integrin Therapy Applications |
WO2013151999A1 (en) | 2012-04-02 | 2013-10-10 | President And Fellows Of Harvard College | Cancer treatment and immune system regulation through fat10 pathway inhibition |
WO2013184912A2 (en) | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
RS58528B1 (en) | 2012-12-03 | 2019-04-30 | Bristol Myers Squibb Co | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
BR112015013127A2 (en) * | 2012-12-04 | 2017-09-26 | Oncomed Pharm Inc | immunotherapy with binding agents |
CN103073644B (en) * | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | Specific anti-mouse TIGIT monoclonal antibody and preparation method, identification and application thereof |
US20140314741A1 (en) | 2013-04-18 | 2014-10-23 | Developmen Center For Biotechnology | Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases |
MY183503A (en) * | 2013-07-16 | 2021-02-23 | Genentech Inc | Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
CA2935285A1 (en) | 2014-02-21 | 2015-08-27 | Medimmune, Llc | Anti-pcsk9-glp-1 fusions and methods for use |
CN107073108A (en) | 2014-07-16 | 2017-08-18 | 豪夫迈·罗氏有限公司 | Use TIGIT inhibitor and the method for anti-cancer agent therapy cancer |
UA122395C2 (en) * | 2014-08-19 | 2020-11-10 | Мерк Шарп Енд Доум Корп. | ANTIBODY AGAINST TIGIT |
WO2016073282A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
PL3221346T3 (en) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
TWI715587B (en) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit-binding agents and uses thereof |
JP6764474B2 (en) | 2015-09-25 | 2020-09-30 | ジェネンテック, インコーポレイテッド | Anti-TIGIT antibody and usage |
-
2015
- 2015-08-17 UA UAA201702456A patent/UA122395C2/en unknown
- 2015-08-17 MY MYPI2017000221A patent/MY184288A/en unknown
- 2015-08-17 AP AP2017009765A patent/AP2017009765A0/en unknown
- 2015-08-17 MY MYPI2020006588A patent/MY198017A/en unknown
- 2015-08-17 MA MA040475A patent/MA40475A/en unknown
- 2015-08-17 US US15/121,624 patent/US20160355589A1/en not_active Abandoned
- 2015-08-17 TN TN2017000024A patent/TN2017000024A1/en unknown
- 2015-08-17 CN CN202110901846.2A patent/CN113583131A/en active Pending
- 2015-08-17 CR CR20170060A patent/CR20170060A/en unknown
- 2015-08-17 IL IL250583A patent/IL250583B/en unknown
- 2015-08-17 KR KR1020197034657A patent/KR102321168B1/en active IP Right Grant
- 2015-08-17 TW TW110113123A patent/TWI790593B/en active
- 2015-08-17 JP JP2017509009A patent/JP6920194B2/en active Active
- 2015-08-17 TW TW104126739A patent/TWI724997B/en active
- 2015-08-17 GE GEAP201514450A patent/GEP20217331B/en unknown
- 2015-08-17 WO PCT/US2015/045447 patent/WO2016028656A1/en active Application Filing
- 2015-08-17 PE PE2017000229A patent/PE20170289A1/en unknown
- 2015-08-17 BR BR112017003108A patent/BR112017003108A8/en active Search and Examination
- 2015-08-17 KR KR1020177007124A patent/KR102050082B1/en active IP Right Grant
- 2015-08-17 CN CN201580056517.5A patent/CN107148430B/en active Active
- 2015-08-17 AU AU2015305754A patent/AU2015305754B2/en active Active
- 2015-08-17 SG SG11201701161QA patent/SG11201701161QA/en unknown
- 2015-08-17 MX MX2017002229A patent/MX2017002229A/en unknown
- 2015-08-17 CA CA2957722A patent/CA2957722C/en active Active
- 2015-08-17 MD MDA20170032A patent/MD4733C1/en active IP Right Grant
- 2015-08-17 JO JOP/2015/0195A patent/JO3664B1/en active
- 2015-08-17 EA EA201790413A patent/EA036311B1/en not_active IP Right Cessation
- 2015-08-17 EP EP15753872.9A patent/EP3183267A1/en active Pending
-
2017
- 2017-02-07 CL CL2017000310A patent/CL2017000310A1/en unknown
- 2017-02-07 ZA ZA2017/00955A patent/ZA201700955B/en unknown
- 2017-02-16 PH PH12017500296A patent/PH12017500296A1/en unknown
- 2017-02-17 NI NI201700019A patent/NI201700019A/en unknown
- 2017-02-17 CO CONC2017/0001561A patent/CO2017001561A2/en unknown
- 2017-02-17 DO DO2017000046A patent/DOP2017000046A/en unknown
- 2017-02-17 MX MX2022001105A patent/MX2022001105A/en unknown
- 2017-02-17 GT GT201700033A patent/GT201700033A/en unknown
- 2017-03-22 US US15/466,113 patent/US20170198042A1/en not_active Abandoned
- 2017-11-20 US US15/817,691 patent/US10618958B2/en active Active
-
2019
- 2019-01-22 AU AU2019200426A patent/AU2019200426B2/en active Active
- 2019-07-10 CL CL2019001926A patent/CL2019001926A1/en unknown
-
2020
- 2020-05-15 US US16/806,658 patent/US20200270346A1/en active Pending
- 2020-06-11 JP JP2020101881A patent/JP7066777B2/en active Active
- 2020-08-05 JO JOP/2020/0192A patent/JOP20200192A1/en unknown
-
2021
- 2021-04-19 AU AU2021202360A patent/AU2021202360A1/en active Pending
-
2022
- 2022-04-27 JP JP2022073522A patent/JP7487256B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200192A1 (en) | Anti-tigit antibodies | |
MX2019012233A (en) | Anti-sirp alpha antibodies. | |
MX2022007522A (en) | Anti-cd27 antibodies. | |
WO2017030823A3 (en) | Anti-tigit antibodies | |
PH12016501763A1 (en) | Multispecific antibodies | |
MX2017008819A (en) | Anti-cd47 antibodies and uses thereof. | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
MX2017008456A (en) | Fused bicyclic compounds for the treatment of disease. | |
AR120118A2 (en) | ANTI-TIGIT ANTIBODIES | |
EA202091619A3 (en) | ANTIBODIES AGAINST TIGIT |